肌酸联合辅酶Q10对帕金森病轻度认知障碍的影响

Effect of Creatine and Coenzyme in the Patients with QIO on Mild Cognitive Impairment Parkinson＇ s Disease

目的：探讨肌酸联合辅酶Q10（CoQl0）对帕金森病（PD）轻度认知功能障碍（PD—MCI）的作用，以及对PD—MCI患者血浆磷脂（PLs）含量的影响。方法：收集2006年6月～2012年6月间参与帕金森病协作研究的75例PD—MCI患者的人口学资料；完成帕金森病统一评定量表第Ⅲ部分（UPDRS-Ⅲ）及蒙特利尔认知评估量表（MoCA）的测评。将75例PD～MCI患者随机分为治疗组和对照组，前者在基本药物治疗的基础上加用一水肌酸5g每日2次口服及辅酶Q10100mg每日3次口服，分别于治疗后12月和18月进行MoCA测评及PLs含量测定。血浆PLs测定采用层析技术结合改良的无机磷定量方法。结果：治疗后12月、18月治疗组和对照组MoCA评分比较均有统计学差异（P〈0．05，P〈0．01）；治疗后12月、18月治疗组血浆PLs含量较对照组显著降低（P〈0．01，P〈0．001）。结论：肌酸联合辅酶Q10治疗可延缓PD—MCI患者认知功能下降速率，并能降低其血浆PLs含量，具有神经保护作用。

OBJECTIVE： To investigate the effect of coenzyme QlO and creatine on mild cognitive impairment （MCI） in the patients with Parkinson＇ s disease and the influence on plasma phospholipids （PLs） levels. METHODS： 75 PD - MCI patients were recruited and collected for the general information. The patients were evaluated by Unified Parkinson＇ s Disease Rating Scale （ UP- DRS ） M and Montreal Cognitive Assessment （MoCA）. According to MoCA scores the patients with PD - MCI were divided into com- bination therapy group （ creatine monohydrate 5g bid and coenzyme Q10 100rag tid orally） and control group （ basic L - dopa or dopa- mine agonist）. Cognitive function was evaluated by MoCA and plasma phopholipids levels were measurad at the twelfth month and the eighteerth month after the treatment. Plasma PLs was assayed by measuring its inorganic phosphorus after separation by chromato- graph. RESULTS： After treatment MoCA scores was significantly higher in treatment group than that in control group. There were sta- tiscally difference （P 〈 0. 05, P 〈 0. 01 respectively）. Plasma PLs levels were significantly decreased in treatment group than those in control group （P 〈0. 01, P 〈0. 001 respectively）. CONCLUSIONS： The treatment of coenzyme Q10 combined with creatine can delay cognitive decline in the patients with PD - MCI and decrease significantly plasma PLs levels in these patients.